CDH13

CDH13

A gene on chromosome 16q23.3 that encodes a cadherin which lacks the cytoplasmic domain characteristic of other cadherins, and thus is not thought to be a cell–cell adhesion glycoprotein. CDH13 downregulates axon growth during neural differentiation, protects vascular endothelial cells from apoptosis due to oxidative stress, and is associated with resistance to atherosclerosis.

Molecular pathology
CDH13 is hypermethylated in many cancers.
References in periodicals archive ?
SNPs in four genes appear for three or more chemicals: GRIP1 (glutamate receptor interacting protein 1), which directs localization of transmembrane proteins; FMN2, a component of p21-based cell cycle arrest; DNER, a transmembrane protein associated with glioblastoma propagation; and the cell membrane cadherin CDH13, an epithelial tumor suppressor.
A study of nearly 800 Finns jailed for both violent and non-violent crimes, and compared to the general population, found variants of two genes, called MAOA and CDH13, to be "associated with extremely violent behaviour".
No substantial signal was observed for either MAOA or CDH13 among non-violent offenders, indicating that findings were specific for violent offending," said the study, published in the journal Molecular Psychiatry.
The study identified several SNPs in a region on chromosome 2 that previously had been linked to alcohol dependence, as well as SNPs in a gene called CDH13 that is located on chromosome 16 and the ADH gene ADH1C on chromosome 4.
This approach has delivered a first gene for ADHD in children, CDH13, encoding a cell-adhesion gene with a role in early brain development.
44) Several genes important in the pathogenesis of pancreatic cancer such as APC, (45) TSLC/IGSF4, (46) SOCS-1, (47) cyclin D2, (48) RASSF1A, (49) WWOX, (50) RUNX3, (51) CDH13, (52) DUSP6, (53) HHIP, (54) and SLC5A8 (55) undergo aberrant methylation, leading to reduced expression or loss of expression.
Frequent promoter methylation and gene silencing of CDH13 in pancreatic cancer.
To further explore the findings that promoter methylation of the certain tumor suppressor genes was associated with early recurrence in NSCLC, a prospective study was designed to analyze the methylation status of ten gene promoters (p16, CDH13, RASSF1A, APC, MGMT, WIF-1, METH-2, GSTP1, SOCS3, DAPK) and correlate status with clinical features, pathologic stage, disease-free survival (DFS) and overall survival (OS).
The replication analyses was performed on two intronic CDH13 SNPs exhibiting the lowest or very low p-values in the discovery phase without being in high linkage disequilibrium with one other (top hit, rs232593, and rs17284098).
htm) for reported associations of CDH13 genetic variants using "CDH13" as the search term and looked up the GWIS result of these SNPs for interaction with [PM.
Nine candidates failed the initial criteria, such as assay length or unsuitable CpG site location for primer and probe placement [BCOR, BCL6 co-repressor; CAV1, caveolin 1, caveolae protein, 22kDa; CD44, CD44 molecule (Indian blood group); CDH13, cadherin 13, H-cadherin (heart); VCAN (formerly CSPG2), versican; FCGR2A, Fc fragment of IgG, low affinity IIa, receptor (CD32); GSK3B, glycogen synthase kinase 3 beta; PCDH17, protocadherin 17; and TAF11, TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 28kDa].
The 15 screened genes were chosen for (a) their demonstrated role in regulating cellular adhesion and their possible role in metastasis (TIMP3, CDH1, CDH13, and APC), or (b) their putative role in carcinogenesis (PPP1R13B, HSPA2, HSD17B4, ESR1, GSTP1, CYP1B1, BRCA1, MYOD1, SOCS1, TITF1, and GSTM3).